It is my pleasure to welcome you to our website and specifically to the section dedicated to the financial community.
Since our IPO in April 2014, we have implemented a development plan to expand the presence of our technology in a global market worth an estimated 6 billion euros.
We have also conducted our first breast fibroadenoma treatments at the University of Virginia in the United States. In Europe, we have obtained approval from the Polish authorities to market our Echopulse® solution and we have signed a distribution agreement with Alteris, a medical equipment supplier operating in the radiology, imaging and teleradiology sectors.
Echopulse® is based on cutting-edge technology and more than ten years of research and development. It is a high-precision technology using High-Intensity Focused Ultrasound (HIFU), guided by ultrasound, to treat breast and thyroid tumours.
Our medical equipment is a disruptive innovation which brings numerous advantages: there is no scarring, patients recover immediately, tumours are significantly reduced in size, and the procedure is much cheaper than current standard treatments. We are now entering the commercial deployment phase and are developing a growth strategy for Europe, the Middle East, the United States and Latin America.
To implement our growth strategy, we have expanded our management team. The new arrivals include our new Marketing Vice-President, Anja Kleber, and myself.
With this strong combination of factors, we are confident that our Echopulse® will succeed. I would like to thank all our employees, partners and shareholders for their trust and support.